As higher rates and slow exits weigh on traditional buyouts, Avista is back with a $1.5 billion lower mid-market healthcare fund, arguing that sector depth, regulatory know-how and recurring revenues are exactly what selective LPs want.
To read the entire story, you must be logged in.
Please log in now or register with us.
